Phil Newman

About

Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.
37 POSTS

/

0 COMMENTS

Articles

Some good news: announcing Longevity2020

In these challenging times, with everyone working from home and conferences pushed-back to later this year, we had an idea: Longevity2020 While the world overcomes...

Talking Longevity investment and risk with R42 Group

Longevity investment is growing and we're seeing a mixture of funds and investment platforms. We chat with the founder of R42 Group. R42 Group actively invents...

Time banking: helping others to help yourself

Time banking is an opportunity for everyone in an aging society but also a lesson for everyone at times of global epidemic: help others...

International Women’s Day: the amazing women of Longevity

As we celebrate International Women's Day we take a look back at some of the women that are pioneering the field of Longevity. Longevity.Technology: International...

The Longevity landscape and investment potential

Hype or hyper-exciting? Kate Batz of Longevity.Capital shares her views on the Longevity landscape and its investment potential: pragmatic optimism, but full of opportunity. In the...

Upgrade Labs: the Longevity clinic of the future?

One of the leaders in health and nutrition came to our London office to talk biohacking, investing, big data and neuroceuticals. Longevity remains open to...

Top 10 articles in February

We've had a big February. Thanks to our growing number of visitors we have increased our traffic by 290% in one month. Boom. Thanks for...

114 year-old cells converted to pluripotent stem cells

AgeX publishes evidence of supercentenarian cellular age reversal: new paper supports hypothesis of no upper age limit for reprogramming cellular aging. This is big...

Megatrends: longer lives and finance sector disruption

Financing Longevity means getting to grips with a collision of megatrends and surfing the Silver Tsunami. In the second of our two-part interview with Margaretta Colangelo, we...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.